.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,601,337

« Back to Dashboard

Claims for Patent: 7,601,337

Title:Delivery of antipsychotics through an inhalation route
Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D (Princeton, NJ), Zaffaroni; Alejandro C (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:11/488,932
Patent Claims: 1. A condensation aerosol for delivery of olanzapine formed by heating a composition containing olanzapine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of olanzapine and less than 5 percent by weight of olanzapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

3. The condensation aerosol according to claim 1 or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0.

4. A condensation aerosol for delivery of trifluoperazine formed by heating a composition containing trifluoperazine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of trifluoperazine and less than 5 percent by weight of trifluoperazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

5. The condensation aerosol according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

6. The condensation aerosol according to claim 4 or claim 5, wherein the geometric standard deviation around the MMAD is less than 3.0.

7. A condensation aerosol for delivery of haloperidol formed by heating a composition containing haloperidol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of haloperidol and less than 5 percent by weight of haloperidol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

8. The condensation aerosol according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

9. The condensation aerosol according to claim 7 or claim 8, wherein the geometric standard deviation around the MMAD is less than 3.0.

10. A condensation aerosol for delivery of loxapine formed by heating a composition containing loxapine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of loxapine and less than 5 percent by weight of loxapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

11. The condensation aerosol according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

12. The condensation aerosol according to claim 10 or claim 11, wherein the geometric standard deviation around the MMAD is less than 3.0.

13. A condensation aerosol for delivery of risperidone formed by heating a composition containing risperidone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of risperidone and less than 5 percent by weight of risperidone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

14. The condensation aerosol according to claim 13, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

15. The condensation aerosol according to claim 13 or claim 14, wherein the geometric standard deviation around the MMAD is less than 3.0.

16. A condensation aerosol for delivery of clozapine formed by heating a composition containing clozapine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of clozapine and less than 5 percent by weight of clozapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

17. The condensation aerosol according to claim 16, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

18. The condensation aerosol according to claim 16 or claim 17, wherein the geometric standard deviation around the MMAD is less than 3.0.

19. A condensation aerosol for delivery of quetiapine formed by heating a composition containing quetiapine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of quetiapine and less than 5 percent by weight of quetiapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

20. The condensation aerosol according to claim 19, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

21. The condensation aerosol according to claim 19 or claim 20, wherein the geometric standard deviation around the MMAD is less than 3.0.

22. A condensation aerosol for delivery of promazine formed by heating a composition containing promazine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of promazine and less than 5 percent by weight of promazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

23. The condensation aerosol according to claim 22, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

24. The condensation aerosol according to claim 22 or claim 23, wherein the geometric standard deviation around the MMAD is less than 3.0.

25. A condensation aerosol for delivery of thiothixene formed by heating a composition containing thiothixene coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of thiothixene and less than 5 percent by weight of thiothixene degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

26. The condensation aerosol according to claim 25, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

27. The condensation aerosol according to claim 25 or claim 26, wherein the geometric standard deviation around the MMAD is less than 3.0.

28. A condensation aerosol for delivery of chlorpromazine formed by heating a composition containing chlorpromazine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of chlorpromazine and less than 5 percent by weight of chlorpromazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

29. The condensation aerosol according to claim 28, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

30. The condensation aerosol according to claim 28 or claim 29, wherein the geometric standard deviation around the MMAD is less than 3.0.

31. A condensation aerosol for delivery of droperidol formed by heating a composition containing droperidol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of droperidol and less than 5 percent by weight of droperidol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

32. The condensation aerosol according to claim 31, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

33. The condensation aerosol according to claim 31 or claim 32, wherein the geometric standard deviation around the MMAD is less than 3.0.

34. A method of forming an olanzapine containing aerosol comprising: (a) heating a composition containing olanzapine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of olanzapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

35. The method according to claim 34, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

36. The method according to claim 35, wherein the coated composition comprises at least 10 percent by weight of olanzapine.

37. A method of forming a trifluoperazine containing aerosol comprising: (a) heating a composition containing trifluoperazine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of trifluoperazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

38. The method according to claim 37, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

39. The method according to claim 38, wherein the coated composition comprises at least 10 percent by weight of trifluoperazine.

40. A method of forming a haloperidol containing aerosol comprising: (a) heating a composition containing haloperidol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of haloperidol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

41. The method according to claim 40, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

42. The method according to claim 41, wherein the coated composition comprises at least 10 percent by weight of haloperidol.

43. A method of forming a loxapine containing aerosol comprising: (a) heating a composition containing loxapine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of loxapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

44. The method according to claim 43, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

45. The method according to claim 44, wherein the coated composition comprises at least 10 percent by weight of loxapine.

46. A method of forming a risperidone containing aerosol comprising: (a) heating a composition containing resperidone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of risperidone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

47. The method according to claim 46, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

48. The method according to claim 47, wherein the coated composition comprises at least 10 percent by weight of risperidone.

49. A method of forming a clozapine containing aerosol comprising: (a) heating a composition containing clozapine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of clozapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

50. The method according to claim 49, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

51. The method according to claim 50, wherein the coated composition comprises at least 10 percent by weight of clozapine.

52. A method of forming a quetiapine containing aerosol comprising: (a) heating a compostion containing quetiapine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of quetiapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

53. The method according to claim 52, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

54. The method according to claim 53, wherein the coated composition comprises at least 10 percent by weight of quetiapine.

55. A method of forming a promazine containing aerosol comprising: (a) heating a composition containing promazine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of promazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

56. The method according to claim 55, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

57. The method according to claim 56, wherein the coated composition comprises at least 10 percent by weight of promazine.

58. A method of forming a thiothixene containing aerosol comprising: (a) heating a composition containing thiothixene coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of thiothixene degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

59. The method according to claim 58, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

60. The method according to claim 59, wherein the coated composition comprises at least 10 percent by weight of thiothixene.

61. A method of forming a chlorpromazine containing aerosol comprising: (a) heating a composition containing chlorpromazine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of chlorpromazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

62. The method according to claim 61, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

63. The method according to claim 62, wherein the coated composition comprises at least 10 percent by weight of chlorpromazine.

64. A method of forming a droperidol containing aerosol comprising: (a) heating a composition containing droperidol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of droperidol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

65. The method according to claim 64, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

66. The method according to claim 65, wherein the coated composition comprises at least 10 percent by weight of droperidol.

67. A method of forming a prochlorperazine containing aerosol comprising: (a) heating a composition containing prochlorperazine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of prochlorperazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

68. The method according to claim 67, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

69. The method according to claim 68, wherein the coated composition comprises at least 10 percent by weight of prochlorperazine.

70. A method of forming a fluphenazine containing aerosol comprising: (a) heating a composition containing fluphenazine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of fluphenazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

71. The method according to claim 70, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

72. The method according to claim 71, wherein the coated composition comprises at least 10 percent by weight of fluphenazine.

73. A condensation aerosol for delivery of prochlorperazine formed by heating a composition containing prochlorperazine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of prochlorperazine and less than 5 percent by weight of prochlorperazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

74. The condensation aerosol according to claim 73, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

75. The condensation aerosol according to claim 73 or claim 74, wherein the geometric standard deviation around the MMAD is less than 3.0.

76. A condensation aerosol for delivery of fluphenazine formed by heating a composition containing fluphenazine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of fluphenazine and less than 5 percent by weight of fluphenazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

77. The condensation aerosol according to claim 76, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

78. The condensation aerosol according to claim 76 or claim 77, wherein the geometric standard deviation around the MMAD is less than 3.0.

79. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine, and fluphenazine, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

80. The method according to claim 79, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

81. The method according to claim 80, wherein the coated composition comprises at least 10 percent by weight of the drug.

82. A method of forming a drug containing aerosol comprising: (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine, and fluphenazine, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

83. The method according to claim 82, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

84. The method according to claim 83, wherein the coated composition comprises at least 10 percent by weight of the salt form of the drug.

85. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool.

86. The condensation aerosol according to claim 5, wherein the condensing comprises allowing the vapor to cool.

87. The condensation aerosol according to claim 8, wherein the condensing comprises allowing the vapor to cool.

88. The condensation aerosol according to claim 11, wherein the condensing comprises allowing the vapor to cool.

89. The condensation aerosol according to claim 14, wherein the condensing comprises allowing the vapor to cool.

90. The condensation aerosol according to claim 17, wherein the condensing comprises allowing the vapor to cool.

91. The condensation aerosol according to claim 20, wherein the condensing comprises allowing the vapor to cool.

92. The condensation aerosol according to claim 23, wherein the condensing comprises allowing the vapor to cool.

93. The condensation aerosol according to claim 26, wherein the condensing comprises allowing the vapor to cool.

94. The condensation aerosol according to claim 29, wherein the condensing comprises allowing the vapor to cool.

95. The condensation aerosol according to claim 32, wherein the condensing comprises allowing the vapor to cool.

96. The condensation aerosol according to claim 74, wherein the condensing comprises allowing the vapor to cool.

97. The condensation aerosol according to claim 77, wherein the condensing comprises allowing the vapor to cool.

98. The method according to claim 35, wherein the condensing comprises allowing the vapor to cool.

99. The method according to claim 38, wherein the condensing comprises allowing the vapor to cool.

100. The method according to claim 41, wherein the condensing comprises allowing the vapor to cool.

101. The method according to claim 44, wherein the condensing comprises allowing the vapor to cool.

102. The method according to claim 47, wherein the condensing comprises allowing the vapor to cool.

103. The method according to claim 50, wherein the condensing comprises allowing the vapor to cool.

104. The method according to claim 53, wherein the condensing comprises allowing the vapor to cool.

105. The method according to claim 56, wherein the condensing comprises allowing the vapor to cool.

106. The method according to claim 59, wherein the condensing comprises allowing the vapor to cool.

107. The method according to claim 62, wherein the condensing comprises allowing the vapor to cool.

108. The method according to claim 65, wherein the condensing comprises allowing the vapor to cool.

109. The method according to claim 68, wherein the condensing comprises allowing the vapor to cool.

110. The method according to claim 88, wherein the condensing comprises allowing the vapor to cool.

111. The method according to claim 80, wherein the condensing comprises allowing the vapor to cool.

112. The method according to claim 83, wherein the condensing comprises allowing the vapor to cool.

113. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine, and fluphenazine, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

114. The method according to claim 113, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

115. The method according to claim 114, wherein the condensation aerosol is formed at a rate greater than 0.75 mg/second.

116. The method according to claim 115, wherein the condensation aerosol is formed at a rate greater than 1 mg/second.

117. The method according to claim 116, wherein the condensation aerosol is formed at a rate greater than 2 mg/second.

118. The method according to claim 113, wherein the condensing comprises allowing the vapor to cool.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc